LENZ LENZ Therapeutics, Inc. | US52635N1037
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 63.179.900 | 18.982.990 | 232.82% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -3,51 | -4,56 | 23.16% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 7 | 7 | 0.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |